about
pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cellsEffect of PEG-PDLLA polymeric nanovesicles loaded with doxorubicin and hematoporphyrin monomethyl ether on human hepatocellular carcinoma HepG2 cells in vitro.A reduction and pH dual-sensitive polymeric vector for long-circulating and tumor-targeted siRNA delivery.Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.Amelioration of cirrhotic portal hypertension by targeted cyclooxygenase-1 siRNA delivery to liver sinusoidal endothelium with polyethylenimine grafted hyaluronic acid.The long-term fate of mesenchymal stem cells labeled with magnetic resonance imaging-visible polymersomes in cerebral ischemia.Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.Near-infrared Light Induced Morphology Transition of Poly(ether amine) Nanoparticles for Supersensitive Drug Release.Preliminary Study of MR and Fluorescence Dual-mode Imaging: Combined Macrophage-Targeted and Superparamagnetic Polymeric Micelles.Superparamagnetic Iron Oxide-Loaded Cationic Polymersomes for Cellular MR Imaging of Therapeutic Stem Cells in Stroke.Construction of negatively charged and environment-sensitive nanomedicine for tumor-targeted efficient siRNA delivery.In vivo monitoring of neural stem cells after transplantation in acute cerebral infarction with dual-modal MR imaging and optical imagingCo-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma ModelDiketopyrrolopyrrole-based carbon dots for photodynamic therapyAortic plaque-targeted andrographolide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammationThe programmed site-specific delivery of the angiostatin sunitinib and chemotherapeutic paclitaxel for highly efficient tumor treatment
P50
Q28540012-9BAAEB95-6B56-42BD-8F17-45CA341272B2Q37372698-68C95243-52A4-4CDA-95E3-DF311128B568Q38943375-0B699A75-68C3-427A-92B4-EFB126A6D06FQ39096735-FE0B7A50-AD6A-4003-9ED5-BD26BEB116E1Q40120933-74A95C67-33DA-4036-9727-53EEC6582B62Q41089568-7BA75949-E56E-456C-98A0-06019404716BQ47378147-93CDE8BE-96BA-4B42-BC6C-16ACBB695F25Q48511779-D8B3E4B4-BCCA-4757-9566-960D069E6F23Q49195272-B77CCC54-91EB-4ADD-AF4F-E3D9B73F18A7Q49715284-61A80C03-52E2-4C2C-949E-B1E9BF50F71DQ51631011-1B781A41-EFFB-4C33-8B55-7472D1E1C105Q87446543-90E27188-DEBB-4F7E-A3A8-5CC7980293D2Q88460235-E09B10B8-21C5-45A0-B029-E2FC8A485AA0Q88948278-9D2A199F-22A6-421D-B602-B62930DD6729Q89380189-FB1D3F8C-C3A5-4712-81A9-63429F43175DQ92614232-E01A86BE-2822-4D04-9CD3-3A1B0880031D
P50
description
researcher ORCID ID = 0000-0002-8349-7555
@en
name
Yong Wang
@ast
Yong Wang
@en
Yong Wang
@es
Yong Wang
@nl
type
label
Yong Wang
@ast
Yong Wang
@en
Yong Wang
@es
Yong Wang
@nl
prefLabel
Yong Wang
@ast
Yong Wang
@en
Yong Wang
@es
Yong Wang
@nl
P106
P31
P496
0000-0002-8349-7555